Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 10Burkitt Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Vomiting 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Nausea 2Smoldering Multiple Myeloma 1Renal Insufficiency 1Prostatic Neoplasms 1Plasmacytoma 1Ovarian Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1Blast Crisis 1

Interventions

Dexamethasone 2melflufen 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1dabrafenib 1belinostat 1auricularum 1Thalidomide 1Pharmacogenomic Testing 1Lenalidomide 1L-melphalanyl-p-L-fluorophenylalanine ethyl ester 1Cyclophosphamide 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Renal Insufficiency × auricularum × Clear all
NCT04352205 2024-07-01

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Emory University

Phase 2 Terminated
17 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡